Dexamethasone Phosphate

證據等級: L5

預測適應症: 0 個

Dexamethasone Phosphate: Evaluation Incomplete — No TxGNN Predictions Available

One-Sentence Summary

Dexamethasone Phosphate is a synthetic glucocorticoid with well-established anti-inflammatory and immunosuppressive properties in clinical use globally. However, no TxGNN predictions were generated for this compound in the current evidence pack — the predicted_indications array is empty. As a result, this report cannot perform a drug repurposing analysis, and a Hold decision is issued pending data remediation.

Quick Overview

Item	Content
Original Indication	Not available (no Taiwan regulatory records found)
Predicted New Indication	Not available (no TxGNN predictions generated)
TxGNN Prediction Score	—
Evidence Level	— (no predictions to evaluate)
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

This section cannot be completed. No predicted indications were returned by the TxGNN model for Dexamethasone Phosphate.

Additionally, detailed mechanism of action data is not available in the current evidence pack (DG002: High severity data gap). Without both a target indication and an MOA, mechanistic bridging analysis is not possible.

Once TxGNN predictions are generated and DrugBank MOA data is retrieved, this section can be populated.

Clinical Trial Evidence

Currently no predicted indication to anchor clinical trial evidence. Please re-run the evidence pipeline after TxGNN predictions are available.

Literature Evidence

Currently no predicted indication to anchor literature evidence. Please re-run the evidence pipeline after TxGNN predictions are available.

Taiwan Market Information

Dexamethasone Phosphate has 0 active authorizations in Taiwan as of the data cut-off (2026-04-20). No license records were returned from the TFDA query.

Note: The TFDA query returned result_count: 0. This may indicate the drug is registered under a different INN variant or brand name. Cross-checking against "Dexamethasone Sodium Phosphate" or formulation-specific entries is recommended.

Safety Considerations

Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, drug interactions) returned no data in this evidence pack. The TFDA package insert query returned result_count: 1 — manual extraction from that document is required (see DG001 remediation below).

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence pack contains no TxGNN predictions and no original indication data, making it impossible to perform a drug repurposing assessment. The two blocking data gaps must be resolved before this candidate can advance.

To proceed, the following is needed:

[Blocking — DG001] Download and parse the TFDA package insert PDF to extract approved indication text, key warnings, and contraindications.
[High — DG002] Query DrugBank API for Dexamethasone Phosphate (or its parent compound Dexamethasone, DB01234) to retrieve MOA, pharmacodynamics, and drug categories.
[Critical] Investigate why predicted_indications is empty — confirm whether the TxGNN model failed to match this INN, or whether the knowledge graph node for this compound is missing. Consider querying under "dexamethasone" (parent compound) rather than the phosphate ester form.
[Advisory] Verify TFDA query logic: the zero-result TFDA search may reflect an INN mismatch. Re-query with "dexamethasone" or "地塞米松" to check for existing licenses.
Once predictions are available, re-run the full evidence collection pipeline (clinical trials + PubMed literature) against the top-ranked predicted indication.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.